Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel. A brief description of the cases can be found below.
case 1 (part of module 1)
Younger fit patient with relapse after high-dose therapy with autologous stem cell transplantation
Agoston Gyula Szabo, MD
Department of Hematology, Rigshospitalet Copenhagen, Denmark
case 2 (part of module 1)
Younger fit patient with relapse after high-dose therapy with autologous stem cell transplantation
Inger Nijhof, MD, PhD
Department of Internal Medicine, St. Antonius Hospital, The Netherlands
case 3 (part of module 1)
A patient refractory to lenalidomide and non-responsive to bortezomib
Fredrik Schjesvold, MD, PhD
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
case 4 (part of module 1)
Patient with early relapse after auto-SCT
Ville Varmavuo, MD PhD
Chief Medical Officer in Education, Internal Medicine, Kotka, Finland
case 5 (part of module 1)
Patient beyond the third line: carfilzomib, lenalidomide, pomalidomide, and anti-CD38 refractory
Valdas Peceliunas, MD
Department of Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
case 6 (part of module 1)
Second line treatment in early relapse
Professor Xavier Leleu, MD, PhD
Department of Hematology, Academic Hospital of Poitiers, France
case 7 (part of module 2)
Early relapse following initial therapy for MM predicts poor outcome, even in the era of novel agents
Isabelle Vande Broek, MD, PhD
Department of Internal Medicine, St. Antonius Hospital, The Netherlands
case 8 (part of module 2)
Extramedullary disease in multiple myeloma: a challenging therapeutic dilemma
Department of Oncology & Hematology, Vitaz, Sint-Niklaas, Belgium
Department of Oncology & Hematology, Vitaz, Sint-Niklaas, Belgium
Disclaimer: The purpose of this e-learning is to provide you as an HCP with relevant information on the basis of which you can draw your own conclusions. This information is not intended to provide recommendations regarding indications, dosages, or other statements not listed in the Summary of Product Characteristics of the products concerned or not listed in the local applicable guidelines for multiple myeloma.
